Lance Washington, MD
Internal Medicine · Kokomo, INNPI 1356312128
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,135 of the $52,575 with a category attached, or 64.9%. 52 manufacturers reported payments, led by AbbVie at 48.8% of the total. Reporting peaked in 2020 at $18,236 and has fallen 52.7% since, to $8,623 in 2025. Among internal medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 820 payments — averaging $64.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$26K
- Phathom Pharmaceuticals, Inc.$15K
- AstraZeneca$2K
- Bayer$2K
- Novo Nordisk$2K
- Biohaven Pharmaceuticals, Inc.$1K
- plus $6K from 46 others
What the payments were for
- Consulting fees$2,8255%
- Speaking & faculty fees$34,13565%
- Travel & lodging$3,3386%
- Food & beverage$12,23523%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$23,306
- VOQUEZNA$14,052
- NURTEC ODT$1,200
- Non-Covered$1,159
- FARXIGA$831
- FreeStyle Libre$358
- VRAYLAR$250
- Wegovy$234
- AIRSUPRA$120
- REXULTI$120
- XARELTO$112
How this compares
$52,575 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 530 | $351,680 |
| OzempicSemaglutide | 189 | $242,765 |
| MounjaroTirzepatide | 143 | $203,757 |
| EliquisApixaban | 353 | $116,094 |
| TrulicityDulaglutide | 87 | $105,871 |
| FarxigaDapagliflozin Propanediol | 112 | $67,660 |
| RexultiBrexpiprazole | 29 | $36,916 |
| XareltoRivaroxaban | 34 | $31,347 |
| WegovySemaglutide | 13 | $27,278 |
| InvokanaCanagliflozin | 18 | $20,270 |
| MyrbetriqMirabegron | 60 | $19,611 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $19,424 |
| TrintellixVortioxetine Hydrobromide | 21 | $19,176 |
| CreonLipase/Protease/Amylase | 15 | $13,201 |
| Atorvastatin Calcium | 983 | $11,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $700 | $309,628230 claims |
| Novo NordiskOzempic, Wegovy | $1,550 | $270,043202 claims |
| PfizerEliquis, Paxlovid, Premarin | $417 | $128,551377 claims |
| AstraZenecaFarxiga | $2,196 | $67,660112 claims |
| Johnson & JohnsonXarelto, Invokana | $793 | $51,61752 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $361 | $36,91629 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $72 | $30,66848 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $19,61160 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $193 | $19,17621 claims |
| AbbVieCreon | $25,661 | $13,20115 claims |
| Sanofi-aventis U.S. LLCAdmelog, Lantus | $39 | $10,413118 claims |
| BayerKerendia | $1,573 | $8,77115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Kokomo
- Abhinav SinghGreenwood$733K
- Girish KunapareddyTerre Haute$329K
- Raj VuppalanchiIndianapolis$279K
- Joseph Arulandula Porte$251K
- Napoleon MamintaIndianapolis$116K
- Jennifer PaisleyLawrenceburg$112K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
- Emily FrankLebanon$100K
- David IloFort Wayne$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.